U.S. markets open in 11 minutes
  • S&P Futures

    -33.75 (-0.98%)
  • Dow Futures

    -299.00 (-1.06%)
  • Nasdaq Futures

    -98.50 (-0.84%)
  • Russell 2000 Futures

    -19.40 (-1.19%)
  • Crude Oil

    -1.06 (-2.66%)
  • Gold

    -1.00 (-0.05%)
  • Silver

    -0.33 (-1.36%)

    -0.0046 (-0.39%)
  • 10-Yr Bond

    -0.0320 (-3.80%)
  • Vix

    +1.78 (+6.33%)

    -0.0017 (-0.13%)

    +0.3100 (+0.30%)

    +81.35 (+0.62%)
  • CMC Crypto 200

    +2.24 (+0.86%)
  • FTSE 100

    -13.87 (-0.24%)
  • Nikkei 225

    -22.25 (-0.09%)

Should You Investigate STERIS plc (NYSE:STE) At US$149?

Simply Wall St

STERIS plc (NYSE:STE) received a lot of attention from a substantial price movement on the NYSE over the last few months, increasing to US$155 at one point, and dropping to the lows of US$137. Some share price movements can give investors a better opportunity to enter into the stock, and potentially buy at a lower price. A question to answer is whether STERIS's current trading price of US$149 reflective of the actual value of the large-cap? Or is it currently undervalued, providing us with the opportunity to buy? Let’s take a look at STERIS’s outlook and value based on the most recent financial data to see if there are any catalysts for a price change.

Check out our latest analysis for STERIS

What is STERIS worth?

Good news, investors! STERIS is still a bargain right now. I’ve used the price-to-earnings ratio in this instance because there’s not enough visibility to forecast its cash flows. The stock’s ratio of 37.63x is currently well-below the industry average of 45.68x, meaning that it is trading at a cheaper price relative to its peers. STERIS’s share price also seems relatively stable compared to the rest of the market, as indicated by its low beta. If you believe the share price should eventually reach its true value, a low beta could suggest it is unlikely to rapidly do so anytime soon, and once it’s there, it may be hard to fall back down into an attractive buying range.

What does the future of STERIS look like?

NYSE:STE Past and Future Earnings, November 19th 2019
NYSE:STE Past and Future Earnings, November 19th 2019

Future outlook is an important aspect when you’re looking at buying a stock, especially if you are an investor looking for growth in your portfolio. Although value investors would argue that it’s the intrinsic value relative to the price that matter the most, a more compelling investment thesis would be high growth potential at a cheap price. With profit expected to grow by 54% over the next couple of years, the future seems bright for STERIS. It looks like higher cash flow is on the cards for the stock, which should feed into a higher share valuation.

What this means for you:

Are you a shareholder? Since STE is currently undervalued, it may be a great time to accumulate more of your holdings in the stock. With a positive outlook on the horizon, it seems like this growth has not yet been fully factored into the share price. However, there are also other factors such as capital structure to consider, which could explain the current undervaluation.

Are you a potential investor? If you’ve been keeping an eye on STE for a while, now might be the time to enter the stock. Its prosperous future outlook isn’t fully reflected in the current share price yet, which means it’s not too late to buy STE. But before you make any investment decisions, consider other factors such as the track record of its management team, in order to make a well-informed investment decision.

Price is just the tip of the iceberg. Dig deeper into what truly matters – the fundamentals – before you make a decision on STERIS. You can find everything you need to know about STERIS in the latest infographic research report. If you are no longer interested in STERIS, you can use our free platform to see my list of over 50 other stocks with a high growth potential.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.